Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 4/20 | 0.56 |
| ▸ | FLT3 | P36888 | 9/20 | 0.56 |
| ▸ | TYRO3 | Q06418 | 8/20 | 0.56 |
| ▸ | MERTK | Q12866 | 7/20 | 0.56 |
| ▸ | GAS6 | Q14393 | 7/20 | 0.56 |
| ▸ | IGF1R | P08069 | 1/20 | 0.53 |
| ▸ | STK17B | O94768 | 1/20 | 0.52 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.52 |
| ▸ | KIT | P10721 | 2/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.51 |
| ▸ | SELP | P16109 | 1/20 | 0.50 |
| ▸ | ULK1 | O75385 | 1/20 | 0.46 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.46 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20533977 | 1.00 | SYK (0.56) | SYKFLT3TYRO3MERTKGAS6 | |
| SCHEMBL3449012 | 0.87 | FLT3 (0.48) | SYKFLT3TYRO3MERTKGAS6 | |
| SCHEMBL3449008 | 0.87 | FLT3 (0.48) | SYKFLT3TYRO3MERTKGAS6 | |
| SCHEMBL4070462 | 0.84 | SYK (0.69) | SYKFLT3IGF1RKITAURKA | |
| SCHEMBL13648587 | 0.84 | SYK (0.69) | SYKFLT3IGF1RKITAURKA | |
| SCHEMBL14498929 | 0.84 | SYK (0.69) | SYKFLT3IGF1RKITAURKA | |
| SCHEMBL3264101 | 0.83 | AURKA (0.54) | SYKFLT3TYRO3MERTKGAS6 | |
| SCHEMBL1916451 | 0.81 | GSK3B (0.67) | SYKFLT3TYRO3MERTKGAS6 | |
| SCHEMBL1918619 | 0.81 | GSK3B (0.67) | SYKFLT3TYRO3MERTKGAS6 | |
| SCHEMBL1916449 | 0.81 | GSK3B (0.67) | SYKFLT3TYRO3MERTKGAS6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180297977-A1 | Novel Pan-TAM Inhibitors And Mer/Axl Dual Inhibitors | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2018-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180297977-A1 | Novel Pan-TAM Inhibitors And Mer/Axl Dual Inhibitors | MERTK, CD274, AXL | SYK 127/4885FLT3 44/4885TYRO3 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.